Physician profile
Tyisha Davis
NPI 1275121055
$12,008.09
in general payments reported to CMS, 2019-2025
25 companies · $3,921 in 2025
The $3,921 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $186 · 2022: $841 · 2023: $2,855 · 2024: $4,205 · 2025: $3,921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $97.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,883.76 |
| Education | $97.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,601.42 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $1,528.86 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $1,007.09 | 2022-2025 | Rexulti, Nuedexta, Abilify Mycite |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,007.06 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $891.97 | 2022-2025 | Auvelity |
| Corium, LLC | $766.26 | 2023-2025 | Azstarys, Azstarys |
| Teva Pharmaceuticals USA, INC. | $738.84 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Lundbeck LLC | $692.30 | 2022-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $682.09 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $648.82 | 2021-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $633.67 | 2023-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $484.39 | 2023-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $301.68 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $227.03 | 2022-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $156.15 | 2022-2024 | Jornay Pm |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $123.83 | 2024-2025 | Tempus Pixel, Tempus Pixel |
| Sage Therapeutics, LLC | $105.83 | 2024-2025 | Zurzuvae |
| Neos Therapeutics, LP | $98.81 | 2024-2025 | Adzenys Xr-Odt |
| Tris Pharma INC | $79.56 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Sunovion Pharmaceuticals INC. | $76.52 | 2022 | |
| Indivior INC. | $66.50 | 2022-2024 | Perseris |
| Collegium Pharmaceutical, INC. | $30.90 | 2025 | Jornay Pm |
| Luye Pharma (USA) LTD. | $21.88 | 2025 | Erzofri Extended-Release |
| Idorsia Pharmaceuticals US INC | $19.24 | 2022 | |
| Almatica Pharma LLC | $17.39 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyisha Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.